FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2975975650> ?p ?o ?g. }

• W2975975650 endingPage "4695" @default.
• W2975975650 startingPage "4688" @default.
• W2975975650 abstract "C-X-C chemokine receptor type 4 (CXCR4) is overexpressed in hematological and solid malignancies. LY2510924 is a potent peptide antagonist of CXCR4. A derivative of LY2510924, BL01, was evaluated for theranostic applications targeting CXCR4. Methods: BL01 was synthesized by solid phase approach. A Lys(ivDde) residue was added at the C-terminus of LY2510924 (cyclo[Phe-Tyr-Lys(iPr)-d-Arg-2-Nal-Gly-d-Glu]-Lys(iPr)-NH2). A DOTA chelator was conjugated to the side chain of the deprotected exogenous Lys residue. The binding affinity of Ga/Lu-BL01 was determined by competitive radioligand binding assays. BL01 was radiolabeled with 68GaCl3 or 177LuCl3. Biodistribution studies were performed in mice bearing Daudi Burkitt’s lymphoma tumor xenografts at selected time points. PET imaging studies were performed with [68Ga]Ga-BL01, with blocking experiments performed with preinjection of LY2510924. The stability of [68Ga]Ga/[177Lu]Lu-BL01 was assessed in mouse plasma. Results: Ga-BL01 and Lu-BL01 have nanomolar affinity for CXCR4. [68Ga]Ga-BL01 was obtained in 58 ± 5% decay-corrected radiochemical yields and >99% radiochemical purity with a molar activity of 40 ± 11 GBq/μmol, while [177Lu]Lu-BL01 was obtained in 65 ± 6% decay-corrected radiochemical yields and >99% radiochemical purity with a molar activity of 120 ± 21 GBq/μmol. [68Ga]Ga-BL01 and [177Lu]Lu-BL01 were excreted primarily through the renal pathway. Daudi xenografts were clearly delineated in PET images with good contrast. On the basis of biodistribution data, tumor uptake of [68Ga]Ga-BL01 was 10.2 ± 2.56% injected dose per gram (%ID/g) at 1 h postinjection (p.i.). Spleen (12.6 ± 2.36 %ID/g) and lungs (13.2 ± 2.98 %ID/g), organs that express CXCR4, had high uptake as well. Preinjection of LY2510924 reduced average uptake of [68Ga]Ga-BL01 in tumors by 88%, demonstrating target specificity. The uptake of [68Ga]Ga-BL01 in tumor increased to 15.3 ± 1.86 %ID/g at 2 h p.i., with improved contrast. [177Lu]Lu-BL01 has similar pharmacokinetics as [68Ga]Ga-BL01 at 1 h p.i. The highest uptake was observed in tumor (14.0 ± 1.11 %ID/g), followed by the lungs (13.0 ± 1.27 %ID/g) and spleen (11.6 ± 1.78 %ID/g). The tumor uptake increased to 16.2 ± 2.69 %ID/g at 4 h p.i., before declining slightly to 10.1 ± 1.41 %ID/g at 24 h p.i. Both compounds were stable in vivo, as no metabolites were observed at 5 min p.i. Conclusions: [68Ga]Ga-BL01 and [177Lu]Lu-BL01 are a promising theranostic pair for imaging and endoradiotherapy of CXCR4-expressing malignancies." @default.
• W2975975650 created "2019-10-03" @default.
• W2975975650 creator A5001536243 @default.
• W2975975650 creator A5006978008 @default.
• W2975975650 creator A5022775390 @default.
• W2975975650 creator A5040772609 @default.
• W2975975650 creator A5043365724 @default.
• W2975975650 creator A5053640698 @default.
• W2975975650 creator A5071598124 @default.
• W2975975650 creator A5077969822 @default.
• W2975975650 creator A5078033153 @default.
• W2975975650 creator A5088723836 @default.
• W2975975650 date "2019-09-23" @default.
• W2975975650 modified "2023-10-03" @default.
• W2975975650 title "[⁶⁸Ga]Ga/[¹⁷⁷Lu]Lu-BL01, a Novel Theranostic Pair for Targeting C-X-C Chemokine Receptor 4" @default.
• W2975975650 cites W1438161774 @default.
• W2975975650 cites W1983466424 @default.
• W2975975650 cites W1989035987 @default.
• W2975975650 cites W1995552970 @default.
• W2975975650 cites W2012415615 @default.
• W2975975650 cites W2019879894 @default.
• W2975975650 cites W2066735451 @default.
• W2975975650 cites W2077974469 @default.
• W2975975650 cites W2080756128 @default.
• W2975975650 cites W2081077945 @default.
• W2975975650 cites W2085876247 @default.
• W2975975650 cites W2088730492 @default.
• W2975975650 cites W2100256417 @default.
• W2975975650 cites W2128532174 @default.
• W2975975650 cites W2142285857 @default.
• W2975975650 cites W2142892314 @default.
• W2975975650 cites W2145151064 @default.
• W2975975650 cites W2153216820 @default.
• W2975975650 cites W2153960708 @default.
• W2975975650 cites W2163844917 @default.
• W2975975650 cites W2169139385 @default.
• W2975975650 cites W2182821457 @default.
• W2975975650 cites W2339037925 @default.
• W2975975650 cites W2344463205 @default.
• W2975975650 cites W2521402543 @default.
• W2975975650 cites W2561193801 @default.
• W2975975650 cites W2704364151 @default.
• W2975975650 cites W2751779876 @default.
• W2975975650 cites W2764273516 @default.
• W2975975650 cites W2891400199 @default.
• W2975975650 doi "https://doi.org/10.1021/acs.molpharmaceut.9b00808" @default.
• W2975975650 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31545614" @default.
• W2975975650 hasPublicationYear "2019" @default.
• W2975975650 type Work @default.
• W2975975650 sameAs 2975975650 @default.
• W2975975650 citedByCount "14" @default.
• W2975975650 countsByYear W29759756502020 @default.
• W2975975650 countsByYear W29759756502021 @default.
• W2975975650 countsByYear W29759756502022 @default.
• W2975975650 countsByYear W29759756502023 @default.
• W2975975650 crossrefType "journal-article" @default.
• W2975975650 hasAuthorship W2975975650A5001536243 @default.
• W2975975650 hasAuthorship W2975975650A5006978008 @default.
• W2975975650 hasAuthorship W2975975650A5022775390 @default.
• W2975975650 hasAuthorship W2975975650A5040772609 @default.
• W2975975650 hasAuthorship W2975975650A5043365724 @default.
• W2975975650 hasAuthorship W2975975650A5053640698 @default.
• W2975975650 hasAuthorship W2975975650A5071598124 @default.
• W2975975650 hasAuthorship W2975975650A5077969822 @default.
• W2975975650 hasAuthorship W2975975650A5078033153 @default.
• W2975975650 hasAuthorship W2975975650A5088723836 @default.
• W2975975650 hasConcept C13965031 @default.
• W2975975650 hasConcept C170493617 @default.
• W2975975650 hasConcept C177322064 @default.
• W2975975650 hasConcept C178790620 @default.
• W2975975650 hasConcept C185592680 @default.
• W2975975650 hasConcept C197404232 @default.
• W2975975650 hasConcept C202751555 @default.
• W2975975650 hasConcept C2777807558 @default.
• W2975975650 hasConcept C2779931791 @default.
• W2975975650 hasConcept C2989005 @default.
• W2975975650 hasConcept C55493867 @default.
• W2975975650 hasConcept C67847695 @default.
• W2975975650 hasConcept C71240020 @default.
• W2975975650 hasConcept C71924100 @default.
• W2975975650 hasConceptScore W2975975650C13965031 @default.
• W2975975650 hasConceptScore W2975975650C170493617 @default.
• W2975975650 hasConceptScore W2975975650C177322064 @default.
• W2975975650 hasConceptScore W2975975650C178790620 @default.
• W2975975650 hasConceptScore W2975975650C185592680 @default.
• W2975975650 hasConceptScore W2975975650C197404232 @default.
• W2975975650 hasConceptScore W2975975650C202751555 @default.
• W2975975650 hasConceptScore W2975975650C2777807558 @default.
• W2975975650 hasConceptScore W2975975650C2779931791 @default.
• W2975975650 hasConceptScore W2975975650C2989005 @default.
• W2975975650 hasConceptScore W2975975650C55493867 @default.
• W2975975650 hasConceptScore W2975975650C67847695 @default.
• W2975975650 hasConceptScore W2975975650C71240020 @default.
• W2975975650 hasConceptScore W2975975650C71924100 @default.
• W2975975650 hasFunder F4320334506 @default.
• W2975975650 hasIssue "11" @default.
• W2975975650 hasLocation W29759756501 @default.
• W2975975650 hasLocation W29759756502 @default.

• next